Vertex Pharmaceuticals (VRTX) Cash from Restructuring (2009 - 2017)

Vertex Pharmaceuticals' Cash from Restructuring history runs 9 years deep, the most recent figure standing at -$2.1 million for Q4 2017.

• On a quarterly basis, Cash from Restructuring fell 392.97% year-over-year to -$2.1 million in Q4 2017; TTM through Dec 2017 was -$6.0 million, a 19.38% increase from a year earlier, with the FY2017 full-year figure at -$6.0 million, up 19.38% from the prior year.
• Cash from Restructuring rose to -$2.1 million in Q4 2017 per VRTX's latest filing, from -$2.8 million in the prior quarter.
• Across five years, Cash from Restructuring topped out at $36.6 million in Q3 2014 and bottomed at -$24.4 million in Q1 2015.
• The 5-year median for Cash from Restructuring is -$1.6 million (2015), against an average of -$1.1 million.
• Biggest YoY gain for Cash from Restructuring was 796.18% in 2014; the steepest drop was 1099.75% in 2014.
• Year by year, Cash from Restructuring stood at $2.2 million in 2013, then tumbled by 540.05% to -$9.7 million in 2014, then soared by 74.96% to -$2.4 million in 2015, then soared by 129.7% to $725000.0 in 2016, then slumped by 392.97% to -$2.1 million in 2017.
• Per Business Quant, the three latest VRTX Cash from Restructuring figures stand at -$2.1 million (Q4 2017), -$2.8 million (Q3 2017), and -$1.4 million (Q2 2017).